Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after a recent share price pullback, with the stock closing at $31.48. Investors are assessing how the current valuation lines up with the company’s fundamentals.
See our latest analysis for Teva Pharmaceutical Industries.
The recent 7 day share price return, down 9.1%, and 1 month share price return, down 7.6%, contrast with a 1 year total shareholder return of 85.7% and 3 year total shareholder return above 3x. This suggests that long term momentum remains strong despite the latest pullback.
If Teva Pharmaceutical Industries has you rethinking where growth could come from next, it may be worth scanning for other opportunities among 40 healthcare AI stocks
With Teva Pharmaceutical Industries trading at $31.48 and sitting at a sizeable discount to some valuation estimates, investors are left with a key question: is this recent weakness opening a window, or is the market already pricing in future growth?
Most Popular Narrative: 23.7% Undervalued
With Teva Pharmaceutical Industries last closing at $31.48 against a narrative fair value of $41.27, the current setup hinges on how durable its mix of branded drugs, biosimilars, and generics really is over the next few years.
The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, powering long-term EBITDA growth.
Curious what earnings path, margin shift, and future profit multiple sit behind that $41.27 figure? The core narrative leans heavily on a changing product mix, firmer profitability expectations, and a valuation multiple that assumes investors stay confident in Teva Pharmaceutical Industries’ long term earnings profile.
Result: Fair Value of $41.27 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, Teva Pharmaceutical Industries still faces meaningful overhangs, including reliance on a handful of branded drugs and a sizeable net debt position that could constrain flexibility if conditions become tighter.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
Next Steps
Given the mixed signals around Teva Pharmaceutical Industries, it makes sense to move quickly, carefully review the evidence on both sides, and weigh the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Teva Pharmaceutical Industries?
If Teva Pharmaceutical Industries has sharpened your focus on valuation and fundamentals, do not stop here. Broader opportunity can sit in very different corners of the market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com